Innovations • Global Impact • In The News • Our People

A Collaborative Netowrk to Support Resilient Vaccine Development Infrastructure

AAHI is coordinating a proposal to establish a collaborative network of Centers of Excellence for Vaccine Innovation and Development (CoEs), to develop affordable and accessible vaccine technologies for readiness rapidly to respond to global health threats.


The latest scientific breakthroughs at AAHI.

Make your products accessible to those who need them most. Collaborate with AAHI.


APRIL 2024

Collaboration across communities.

Explore AAHI's different areas of impact.

Los Cabos, Mexico

AAHI To Present on Regional Development and Manufacturing of Vaccines at the Vaccine Technology IX Conference

Christopher Fox, PhD, Senior Vice President, Formulations will share his experience and expertise transferring adjuvant formulation manufacturing technology around the world to provide accessible and affordable vaccine development solutions. AAHI has successfully transferred adjuvant production technology to Romania and Brazil under Dr. Fox's leadership, with support from The WHO's Global Action Plan for Influenza Vaccines (GAP). The COVID-19 pandemic highlighted that building local vaccine production capacity is paramount to a successful response to emerging health threats. 

Learn more at the Vaccine Technology IX Conference in Los Cabos May 19-24, convening global vaccine experts to discuss how to advance vaccines for global needs - Advancing Vaccine Technologies for a Healthier World. 

Help us make impossible vaccines possible.


By Linda Geddes


Parasitic diseases, many of which are classified as neglected tropical diseases by the World Health Organization, are a leading cause of high morbidity and mortality in low- and middle-income countries. The incidence of parasitic infections continues not only to rise, but to grow and spread around the world, with new cases reported in the United States. While not always fatal, parasitic diseases significantly impair health and quality of life. Hookworm and schistosomiasis, for example, cause anemia (a reduced number of oxygenated blood cells circulating in the body) and detract from a child's ability to participate fully in school, or an adult's ability to perform at work. Such parasitic diseases are particularly dangerous for pregnant women and their unborn children. Parasitic diseases perpetuate poverty in developing nations, and vaccines preventing infection could immensely improve quality of life. 

Vaccines that have demonstrated promise to prevent or treat parasitic disease rely on the immune-stimulating effect of adjuvant formulations to provide effective protection. AAHI is proud to be providing its adjuvant formulations for use in multiple schistosomiasis vaccine candidates, Baylor College of Medicine's hookworm vaccine candidate, and various malaria vaccine candidates, and to have developed a leishmaniasis vaccine candidate with proven safety and immune-enhancing effects. 


Collaboration across communities.

Explore our different areas of impact.

Openings and Opportunities


The Research Associate I/II will be responsible for executing studies in support of analytical and formulation development of active pharmaceutical ingredients for the development of vaccines and infectious diseases.

Learn more about our formulation technology

We partner with biotech leaders to develop vaccines and more.

Synthetic TLR4 ligand in squalene nanoemulsion

Synthetic TLR4 ligand in QS- 21 containing liposome

Synthetic TLR4 ligand in aqueous formulation

Dual agonist containing both TLR4 and TLR7/8 ligands

2nd-Gen synthetic TLR4 ligand
in squalene nanoemulsion

2nd-Gen synthetic TLR4 ligand
in QS-21 containing liposome

2nd-Gen synthetic TLR4 ligand
in aqueous formulation

Alum nanoparticle formulation, customized particle size

Synthetic TLR7/8 ligand in
squalene nanoemulsion

Synthetic TLR7/8 ligand
adsorbed to aluminum

Synthetic TLR7/8 ligand in
aqueous formulation

Nanostructured lipid carrier

See how our formulations are being used.